APA (7th ed.) Citation

J, F., S, K., F, M. F., A, Z., L, A., M, T., . . . GH, L. (2026). Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis. PharmacoEconomics - open, 10(4), 733. https://doi.org/10.1007/s41669-026-00651-0

Chicago Style (17th ed.) Citation

J, Flanigan, Kane S, Mirzayeh Fashami F, Zhou A, Almuallem L, Tindal M, Schauf M, Li E, and Lyman GH. "Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis." PharmacoEconomics - Open 10, no. 4 (2026): 733. https://doi.org/10.1007/s41669-026-00651-0.

MLA (9th ed.) Citation

J, Flanigan, et al. "Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis." PharmacoEconomics - Open, vol. 10, no. 4, 2026, p. 733, https://doi.org/10.1007/s41669-026-00651-0.